Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Massachusetts General Hospital
Information provided by (Responsible Party):
Thomas J. Spencer, MD, Massachusetts General Hospital Identifier:
First received: June 21, 2012
Last updated: May 30, 2014
Last verified: May 2014

The purpose of this study is to a) assess the efficacy of naltrexone in preventing stimulant-induced euphoria in adults with ADHD, b) assess whether naltrexone will interfere with the clinical efficacy of stimulants in treating adults with ADHD, c) assess whether naltrexone will interfere with the effects of stimulants on neurotransmitter activity. We predict that naltrexone will successfully prevent stimulant-induced euphoria without interfering with the ability of stimulants to effectively treat ADHD in adults. This study will be an 8 -week trial with young adults (18-24) with ADHD.

Condition Intervention Phase
Stimulant-Induced Euphoria
Drug: Naltrexone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Efficacy [ Time Frame: 6 Weeks ] [ Designated as safety issue: No ]
    Efficacy (positive, or 'liking' response to stimulant medication) will be assessed by the change in the Drug Rating Questionnaire - Subject (DRQ-S).

Estimated Enrollment: 100
Study Start Date: September 2012
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Naltrexone
Arm 1: Naltrexone + SODAS MPH
Adults with ADHD will receive open-label SODAS MPH
Other Name: Ritalin LA
Drug: Naltrexone
Subjects randomized to the "active" double-blind group will receive Naltrexone HCl
Other Name: Naltrexone HCl
Placebo Comparator: Placebo
Arm 2: Placebo + SODAS MPH
Adults with ADHD will receive open-label SODAS MPH
Other Name: Ritalin LA


Ages Eligible for Study:   18 Years to 24 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  1. Male or female adults ages 18-30 years.
  2. A diagnosis of ADHD, per clinical evaluation
  3. At least a minimal likeability response (> 5) on the DRQ-S after an initial test dose of 60mg of IR MPH.
  4. Baseline ADHD severity of > 24 on the AISRS.
  5. Able to participate in blood draws and to swallow pills.
  6. Able to understand the nature of the study, to sign an informed consent document and to be considered reliable reporters


  1. Any current (last month), non-ADHD Axis I psychiatric conditions
  2. Significant current anxiety or depression based on Ham-D > 16, BDI > 19, or Ham-A > 21
  3. Any clinically significant chronic medical condition, including cardiovascular disease or hypertension
  4. Clinically significant abnormal baseline laboratory values
  5. I.Q. < 80
  6. Organic brain disorders
  7. Seizures or tics
  8. Pregnant or nursing females
  9. Clinically unstable psychiatric conditions (i.e. suicidal behaviors, psychosis)
  10. Current or recent (within the past year) substance abuse/dependence
  11. Current use of other psychotropic medication(s)
  12. Current or prior adequate treatment with MPH
  13. Known hypersensitivity to methylphenidate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01673594

Contact: Rebecca Grossman, B.S. 617-643-1432

United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Ariana Koster    617-724-2858   
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Thomas J Spencer, MD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: Thomas J. Spencer, MD, Associate Chief, Clinical and Research Program, Pediatric Psychopharmacology, Massachusetts General Hospital Identifier: NCT01673594     History of Changes
Other Study ID Numbers: 2012-P-000918
Study First Received: June 21, 2012
Last Updated: May 30, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Massachusetts General Hospital:
Stimulant-Induced Euphoria
Substance Abuse

Additional relevant MeSH terms:
Central Nervous System Agents
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 24, 2014